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Abstract-The effects of thiosemicarbazone derivatives of 2-acetylpyridine on mammalian and viral 
ribonucleoside diphosphate reductases were investigated. The enzymes were partially purified from 
uninfected and herpes simplex virus type-l (HSV-l)-infected KB cells by sequential salt fractionation 
with streptomycin sulfate and ammonium sulfate and by affinity chromatography on ATP-agarose. The 
five thiosemicarbazone derivatives investigated were all potent inhibitors of the virus-induced reductase. 
Fifty percent inhibitory concentrations (qO values) range from 2 to 13 PM. Four of the five derivatives 
also were inhibitors of the host cell reductase (1~~” values = 7-34 PM). A semicarbazone was inactive 
against the cellular enzyme and relatively weak as an inhibitor of the viral enzyme (ICY” = 340 PM). 
Four of the six compounds were preferential inhibitors of the viral reductase based on a comparison of 
ICY,, values (5 to >85-fold difference). Kinetic experiments revealed that inhibition of the HSV-1 
reductase by the thiosemicarbazones was noncompetitive with respect to CDP and dithiothreitol. A 
comparison of the inhibitory effects of 2-acetylpyridine thiosemicarbazone itself on viral reductase and 
on virus replication in vitro demonstrated a similarity in the dose-response relationships for the two 
parameters. This observation supports the hypothesis that the HSV-induced ribonucleoside diphosphate 
reductase is an important target for the design of antiviral drugs. 
A series of thiosemicarbazone derivatives of 
2-acetylpyridine has been synthesized by Klayman et 
al. [l, 21 as potential antimalarial agents. Screening 
of the compounds against other pathogenic organ- 
isms revealed that the compounds also possessed 
additional antiparasitic [3], antimicrobial [4,5], and 
antineoplastic [6] activity. We have since discovered 
that a number of these compounds are active against 
herpes simplex virus types 1 and 2 (HSV-1 and HSV- 
2) and that some of the derivatives inhibit the in vitro 
replication of the virus to a greater extent than they 
inhibit cellular DNA or protein synthesis [7], To date 
we have examined 111 derivatives and have found 
that certain compounds are active both in vitro and 
in a cutaneous herpes guinea pig model [8]. 
Extensive study into the mechanism of action of 
these derivatives in uninfected mammalian cells has 
led us to conclude that inhibition of ribonucleotide 
reductase (ribonucleoside diphosphate reductase, 
EC 1.17.4.1) is the primary cytotoxic effect of these 
compounds.? This finding is in agreement with 
reports by others on the mode of action of related 
classes of thiosemicarbazones in uninfected cells [9]. 
Mammalian ribonucleotide reductase, a key enzyme 
in the de nmo synthesis of DNA, catalyzes the 
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reduction of ribonucleoside diphosphates to the cor- 
responding 2’-deoxyribonucleoside diphosphates 
[lOI. 
Herpes simplex viruses induce the formation of a 
unique ribonucleoside diphosphate reductase fol- 
lowing infection [ll-151. Unlike cellular reductase, 
the HSV-induced enzyme is free of allosteric control 
[16-181. This permits the buildup of large deoxy- 
nucleotide pools necessary for viral DNA repli- 
cation. Cohen et al. [19] have presented evidence 
that the virus-induced enzyme is composed of two 
non-identical subunits (Hl and H2) which are dif- 
ferent from the corresponding subunits (Ml and M2) 
of the mammalian enzyme. 
The fact that cellular and viral reductases are 
biochemically distinct [ 16-181 suggests that they may 
be differentially affected by inhibitors of ribo- 
nucleotide reduction. If so, the virus-induced 
reductase might have the potential to serve as a 
target for antiviral drugs. There is, however, little 
evidence in the literature to support this hypothesis. 
For example, the two enzymes appear to be about 
equally sensitive to hydroxyurea [17-201: this led 
Nutter et al. [20] to speculate that the HSV-2 
reductase is not an effective target for antiviral drugs. 
Similarly, the viral enzyme is slightly less sensitive 
to guanazole and 4-methyl-5-amino-l-formyliso- 
quinoline thiosemicarbazone (MAIQ) than is the 
cellular enzyme [19,21]. On the other hand, Nakay- 
ama et al. [22] found the viral enzyme to be slightly 
more sensitive to inhibition by E-5(2-bromovinyl)- 
dUTP and 2’-fluoro-5iodo-ara-CTP than was the 
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cellular enzyme. Similarly, Shannon et al. * found the 
viral reductase to be 20-fold more sensitive than the 
cellular enzyme to the 5’-triphosphate of the antiviral 
drug vidarabine (ara-A). This observation, however, 
conflicts with those of Langelier and Buttin [17] 
and Averett et al. [18] who could not demonstrate 
inhibition of the viral enzyme by ara-A-triphosphate. 
In this study we have examined whether HSV- 
l-induced ribonucleoside diphosphate reductase is 
sensitive to derivatives of 2-acetylpyridine thio- 
semicarbazone and whether this inhibition is respon- 
sible for the antiviral effect of these compounds. We 
have found that these derivatives not only inhibit the 
virus-specified enzyme, but that some do so without 
appreciably inhibiting the cellular enzyme. To our 
knowledge, such potent and selective inhibition of 
HSV ribonucleotide reductase has not been reported 
previously. 
MATERIALS AND ~THODS 
Chemicals. Nucleotides, nucleosides, bovine 
serum albumin (fraction V) and dithiothreitol 
(DTT) were purchased from the Sigma Chemical 
Co., St. Louis, MO. HEPES [4-(2-hydroxyethyl)-l- 
piperazine-ethanesulfonic acid] buffer was obtained 
from the Calbiochem-Behring Corp., La Jolla, CA. 
Agarose-hexane-ATP (ATP-agarose, type 3, linked 
via C-8 of the purine ring) was obtained from Phar- 
macia P-L Biochemicals, Inc., Milwaukee, WI. 
Streptomycin sulfate was obtained from Pfizer Lab- 
oratories, New York, NY. Ammonium sulfate (ultra 
pure grade) was purchased from Schwartz Mann, 
Cambridge, MA. [5-3H]CDP (16 to 19.3 Ci/mmole) 
was obtained from the Amersham Corp., Arlington 
Heights, IL. Thiosemicarbazone and semicarbazone 
derivatives of 2-acetylpyridine were provided by Dr. 
Daniel L. Klayman, Walter Reed Army Institute of 
Research, Washington, DC. Methisazone was 
obtained from Dr. P. D. Cook, Warner-Lambert/ 
Parke-Davis Co., Ann Arbor, MI. 
Cell couture techniques and uirus prupagution. KB 
cells, an established human cell line derived from an 
epidermoid carcinoma of the mouth, and the HF 
strain of HSV-1 were obtained from Dr. CJ. H. 
Cohen, University of Pennsylvania, Philadelphia, 
PA. The routine growth and passage of cells, the 
propagation and titration of virus stocks, and the 
detection of mycoplasma contamination have been 
described previously 1231. 
Enzyme pur@cation. Uninfected KB cells were 
grown to mid-log phase as monolayers either in 32- 
oz. glass prescription bottles (Brockway Glass Co., 
Brockway, NJ) or in 850cm* plastic roller bottles 
(Corning Glassworks, Corning, NY ). Cells were har- 
vested by scraping, were washed in HEPES-buffered 
saline [24], and were collected by centrifugation at 
8OOg. Cell pellets were stored at -76” until needed. 
Monolayers infected with HSV-1 at a multiplicity of 
infection (moi) of five plaque-forming units per cell 
were harvested by similar procedures 12 hr post- 
infection. In our hands, this combination of moi and 
* W. M. Shannon, R. W. Brockman, G. Arnett and S. 
Shaddix, FirstAm. Sot. Viral. Meeting. Ithaca, NY (1982). 
incubation time provided the highest enzyme specific 
activity. 
All subsequent steps were done at &5”. Pellets 
were thawed, resuspended in buffer A (20mM 
HEPES, pH 7.6,2 mM DTT), and sonicated in eight 
15set pulses using a Bronwill Sonicator (Bronwill 
Scientific Inc., Rochester, NY). Lysates were clari- 
fied by centrifugation at 100,OOOg for 60min. The 
resulting supernatants were fractionated by sequen- 
tial protein precipitations at final concentrations of 
1% streptomycin sulfate, 27% saturation with 
(NH4)$04 and 41% saturation with (NH&SO4 per- 
formed by the method of Huszar and Bacchetti 1161. 
Pellets from the salt fractions were redissolved in l- 
2 ml of buffer A and dialyzed against buffer A, along 
with aliquots of the 100,OOOg supernatant fraction. 
Selected fractions were further purified by affinity 
chromatography utilizing ATP-agarose by a method 
patterned after that of Spector and Averett 118,251. 
Protein from the salt fractions was first reprecipitated 
at 50% (NH&SO4 saturation, pelleted, resuspended 
in 0.5 ml buffer B (20 mM HEPES, pH 7.6, 2 mM 
DTT, 2mM magnesium acetate), and dialyzed 
against buffer B as described previously. After 
clarification by centrifugation, the preparation was 
applied to an 0.8 X 12.3 cm column of ATP-agarose 
and eluted sequentially with buffer B and buffer B 
containing either 1 M KC1 or 2 mM ATP at a flow 
rate of 3-Sml/hr. The two protein fractions were 
pooled and dialyzed against buffer B. All prep- 
arations were stored at -76”. 
Enzyme assays. Separate, selective assay con- 
ditions were used for the viral and cellular 
reductases. Based upon the observations of Averett 
et al. [18], we found that the viral enzyme was fully 
active in the absence of ATP and Mg’+, whereas the 
cellular enzyme had an absolute requirement for 
ATP and Mg2+. This difference plus different Dm 
concentrations and pH optima provided conditions 
under which cellular reductase activity was inhibited 
>97% when assayed under viral assay conditions and 
viral reductase activity was inhibited >99% when 
assayed under cellular assay conditions. 
The standard reaction mixture for assay of the 
viral reductase contained, in a final volume of 100 ,ul, 
60 mM HEPES at pH 8.0,26 mM DTT, 1-11 ,uCi of 
[3H]CDP (0.52-12pM), and enzyme. In contrast, 
reaction mixtures for assay of the cellular reductase 
contained HEPES at pH7.2, 7mM DTT, 1 mM 
ATP, 1 mM magnesium acetate, [3H]CDP, and 
enzyme. After incubation at 37” for 5-30 min, reac- 
tions were terminated by heating at 95” for 2 min. 
Depletion of substrate ([ 3H]CDP) by interfering 
enzyme activities was assayed by TLC on poly- 
ethyleneimine (PEI)-cellulose 1261. Aliquots (3 yl) 
were removed from reaction tubes and applied to 
TLC plates prespotted with Cyd, CMP, CDP and 
CTP. Ascending development in 0.1 M LiCl-1 N 
acetic acid separated the standards. Because of the 
low amount of reduction during the assays (<5%), 
no attempt was made to separate the deoxy analogs 
from their ribosyl counterparts (mobilities identical). 
The four distinct areas were visualized under U.V. 
light (254 nm), cut from the plates, and eluted with 
0.75 ml of 1 M MgCIZ. After the addition of 5 ml of 
Aqueous Counting Scintillant (Amersham Corp.), 
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label was quantitated in a liquid scintillation spec- 
trometer. The amount of radioactivity which co- 
chromatographed with the nucleoside triphosphate 
spot in assays containing ATP and Mg*+ (cellular 
assay reaction mixtures) was taken as a measure of 
nucleotide kinase activity. The amount of radio- 
activity which co-chromatographed with the nucleo- 
side monophosphate and nucleoside spots in assays 
without ATP and Mg2+ (viral assay reaction 
mixtures) was taken as a measure of phosphatase 
activity. 
HC104 (20 ~1) was added to the remainder of the 
reaction mixtures to give a final concentration of 1 N. 
Incubation at 95” for 15 min converted nucleoside 
di- and triphosphates to monophosphates. Mixtures 
were neutralized to pH 6-7 with 20 ~1 KOH/K&Os, 
the precipitate was pelleted, and 5 ~1 of the super- 
natant fraction was applied to PEI-cellulose TLC 
plates prespotted with UMP, CMP, dCMP, dUMP, 
dTMP and Cyd. Ascending development in H20 
saturated with boric acid and neutralized to pH7 
separated all pyrimidine deoxyribonucleoside mono- 
phosphates from corresponding ribonucleoside 
monophosphates and from nucleosides plus bases. 
These three distinct areas were cut from the plates 
and eluted, and label was quantitated as previously 
mentioned. The amount of radioactivity which co- 
chromatographed with the deoxyribonucleotide spot 
was used as the measure of reductase activity. 
Protein determination. Protein was determined by 
the method of Peterson [27]. Bovine serum albumin 
was used as the standard. 
RESULTS 
Isolation of viral and cellular ribonucleotide 
reductases. HSV-l-induced reductase was separated 
from the host cell enzyme by salt fractionation with 
(NH4)*S04 using the methodology of Huszar and 
Bacchetti [ 161. The desired viral enzyme precipitated 
at 27% saturation. Salt fractionation of uninfected 
cells gave a source of host cell reductase which pre- 
cipitated between 27 and 41% saturation. The two 
enzyme activities differed biochemically as has been 
reported by others [16-181. For example, the cellular 
enzyme had an absolute requirement for ATP (maxi- 
mum activity at 1 mM) whereas the viral enzyme was 
inhibited in its presence. The cellular enzyme was 
approximately sixty times more sensitive to inhi- 
bition by dTTP, a known allosteric inhibitor of ribo- 
nucleotide reductase, than was the viral enzyme 
[50% inhibitory concentrations (rcso values) = 8 and 
450 PM respectively]. The two enzymes also differed 
in their pHoptima and in their requirements for 
D’M as detailed in Materials and Methods. 
The degradation of substrate ([3H]CDP) by our 
preparations also was examined. Table 1 illustrates 
that the fractionation procedure for infected cells 
removed 96% of the kinase activity and 98% of the 
phosphatase activity from the 0 to 27% (NH&SO4 
fraction while leaving 96% of the reductase activity. 
Thus, when examined under viral reductase assay 
conditions (no ATP or Mg*+, thereby suppressing 
kinase activity), the preparation was highly enriched 
in reductase activity and was low in interfering 
activities. 
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The fractionation procedure for uninfected cells 
resulted in the elimination of 91 and 38%, respect- 
ively, of the kinase and phosphatase activities from 
the 27 to 41% (NHJ2S04 fraction. There was, how- 
ever, a 65% loss of reductase activity resulting in a 
low ratio of reductase to kinase. To remove 
additional kinase, this fraction was passed through 
an ATP-agarose column using the method of Spector 
and Averett [25]. This procedure reduced the kinase 
activity to 0.1% of that found in the 100,000 g super- 
natant fraction. Even though reductase activity also 
was lost, the striking loss of kinase resulted in a 20- 
fold improvement of the ratio of reductase to kinase 
(Table 1). The apparent increases in phosphatase 
specific activity may have been from increases in 
available substrate due to decreases in kinase 
activity. Nevertheless, the amount of phosphatase 
activity was not significant when measured under 
cellular reductase assay conditions (ATP and Mg2+ 
present). Even though this procedure did not elim- 
inate all degradation of substrate, we found that 80% 
of CDP remained at the end of 30-min incubations 
with the ATP-agarose-purified preparation com- 
pared to 14% after 30-min incubations with the 
(NH&SO4 fraction. Significantly, no differences in 
inhibition by the thiosemicarbazones were observed 
between the (NH&SOrpurified and the column- 
treated preparations. 
Effects of thiosemicarbazone derivatives on viral 
and cellular ribonucleotide reductase. Using the 
enzymes derived from the salt fractions and the ATP- 
agarose column (listed in Table l), we determined 
dose-response relationships for 2-acetylpyridine 
thiosemicarbazone (the parent compound), four N4- 
monosubstituted derivatives and 2-acetylpyridine 
semicarbazone. Table 2 illustrates that all of the 
derivatives were inhibitors of HSV-l-induced ribo- 
nucleotide reductase, although the semicarbazone 
analog (compound 6) was significantly less potent 
than the corresponding thiosemicarbazone (com- 
pound 1). The parent compound and the N4-methyl, 
-ally1 and -benzyl derivatives (compounds l-4) also 
inhibited the cellular enzyme. Based upon a com- 
parison of lcso values, the parent compound, the N4- 
methyl and -picolyl derivatives and the semi- 
carbazone (compounds 1, 2, 5 and 6) were 5, 8, 
>85 and ~16 times, respectively, more potent as 
inhibitors of the viral enzyme. In contrast, since 
there was complete overlap of 95% confidence in- 
tervals, compounds 3 and 4 showed no selectivity 
Table 2. Inhibition of viral and cellular ribonucleoside diphosphate reductase by derivatives of 
2-acetylpyridine thiosemicarbazone 
C=N-NH-C-NH-R 
No.l- X R 
HSV-1 induced 
reductase Cellular reductase 
1 S H 2.0 (1.5-2.5) 10 (4.9-22) 
2 S CH3 4.2 (3.4-4.8) 34 (11-150) 
3 S CH,CH=CH, 9.4 (5.5-16) 12 (0.47-140) 
4 S CHZ 
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Reductase assays were performed by the general protocol detailed in Materials and Methods 
using the (NH4)2S04 and affinity column-purified protein fractions characterized in Table 1. 
Enzyme dilutions were used such that a minimum of 1,500cpm were converted to product in 
control assays. Six to eight selected concentrations of compounds were assayed at a minimum of 
the two following substrate concentrations: 0.5 PM [3H]CDP (1 &i; approximately 0.5 X K,) and 
12 PM [3H]CDP (2-4 ,Ki; approximately 10 X K,,,). No apparent difference in response was noted 
at the different substrate levels. Compounds were initially dissolved in dimethyl sulfoxide (DMSO) 
and assayed at a final concentration of 2.5% DMSO. 
* Each compound was assayed in two to four experiments and the resulting data were combined 
to construct a single dose-response curve for each enzyme. The 50% inhibitory concentration 
(q,,) values and corresponding 95% confidence intervals listed in parentheses were determined 
by linearly regressing probit values of the percent inhibition of reductase activity against log drug 
concentrations using the methods described by Goldstein [28]. 
t Commonly employed systematic chemical names for the compounds are as follows: compound 1, 
2-acetylpyridine thiosemicarbazone; compound 2, 2-acetylpyridine 4-methyl-3-thiosemicarbazone; 
compound 3, 2-acetylpyridine 4-allyl-3-thiosemicarbazone; compound 4, 2-acetyl- 
pyridine 4-benzyl-3-thiosemicarbazone; compound 5, 2-acetylpyridine 4-picolyl-3-thiosemi- 
carbazone; and compound 6, 2-acetylpyridine semicarbazone. 
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Fig. 1. Dixon plot of the inhibition of virus-induced ribo- 
nucleoside diphosphate reductase by 2-acetylpyridine thio- 
semicarbazone (compound 1). Viral reductase assays were 
performed by the general protocol detailed in Materials 
and Methods using the (NH&SO., fraction characterized 
in Table 1. Standard viral reaction mixtures contained 18 ,ug 
enzyme and [3H]CDP (1 or 2 &i/assay) at the con- 
centrations indicated; incubations were for 15 min. Rate of 
product formation was linear with respect to time for at 
least 15 min. The r* values of the regression lines are 0.95, 
0.94 and 0.98 for 0.52, 2.5 and 11 ,uM CDP respectively. 
The common intersection of the three lines on the x- 
axis indicates noncompetitive inhibition [30]. A double- 
reciprocal plot of the data according to Lineweaver and 
Burk (not shown) gave a common intersection on the x- 
axis, also indicative of noncompetitive inhibition [30]. 
between inhibition of viral and cellular reductases. 
Methisazone (1-methylisatin-Pthiosemicarbazone; 
MIBT), reported to possess antiviral activity against 
vaccinia but poor activity against HSV-1 [29], did 
not inhibit the viral reductase at concentrations of 
up to 107 ,uM (data not shown). 
Kineticproperties of ribonucleotide reductases. The 
kinetic properties of ribonucleotide reductase 
activity and its inhibition were examined. K,,, con- 
centrations for CDP (derived from Woolf plots) 
obtained in four and two separate experiments were 
1.2 and 2.2 PM for viral and cellular reductases 
respectively. Inhibition of viral reductase by 2-ace- 
tylpyridine thiosemicarbazone (compound 1) was 
noncompetitive with respect to CDP (Fig. 1). From 
this plot and another experiment, an average Ki 
concentration of 1.4 PM was derived. A similar 
experiment with cellular reductase gave a Ki con- 
centration of 1.2 PM. Inhibition of viral reductase by 
the N4-methyl derivative (compound 2) also was 
noncompetitive, with a Ki concentration of 3.6 ,uM. 
The effect of DTT on the inhibition of viral 
reductase by 2-acetylpyridine thiosemicarbazone 
also was examined. Reductase activity was measured 
at different fixed concentrations of DTT in the pres- 
ence of selected concentrations of drug. A plot of 
the reciprocal of enzyme velocity versus drug con- 
centration was made for each DTT concentration 
and indicated that inhibition was noncompetitive 
with respect to DTT (data not presented). 
Comparison of the inhibitory effects of 2-ace- 
tylpyridine thiosemicarbazone on viral reductase and 
on virus replication. The effect of the parent com- 
pound on these parameters was compared as a test 
of the hypothesis that inhibition of the viral reductase 
6 
E 96- 0 0 
u 
7.0 






HSV- I Replication 6.0 
bg 60 8 X 








b-m 30- . \ 
a 
SE 













I I I I 1,111, I I I,,,&_ 
0.1 1.0 IO 100 
CONCENTRATION OF COMPOUND 1 (/LMI 
Fig. 2. Comparison of inhibition of viral ribonucleoside 
diphosphate reductase with inhibition of the in uitro rep- 
lication of HSV-1 by 2-acetylpyridine thiosemicarbazone 
(compound 1). Reductase inhibition data (0) used to deter- 
mine the lcso given in Table 2 are presented and represent 
the combined results of three experiments. Virus rep- 
lication data (0), representing the combined results of two 
yield reduction experiments, were reported previously [7]. 
Probit values of percent inhibition were linearly regressed 
against log drug concentration using the methods described 
by Goldstein [28]. The r2 values of the regression lines are 
0.82 and 0.88 for reductase and virus replication inhibition 
respectively. The identity of the two dose-response curves 
was tested by calculating P values for the equality of 
regressions and slopes [31]. 
was responsible for inhibition of virus replication. 
Dose-response relationships were constructed and 
compared (Fig. 2). Visual inspection of the data 
show that inhibition of viral reductase is similar to 
inhibition of virus replication. Statistical comparison 
of the two dose-response lines indicated that the two 
lines were separate (comparison of slopes: P = 0.013, 
comparison of regressions: P < 0.001) with a slightly 
greater inhibition of reductase activity. Although 
no simple comparison of dose-response effects on 
potentially related phenomena can prove a causal 
relationship, a marked dissimilarity can disprove 
such a relationship. In this case, because inhibition 
of the two phenomena is similar and because inhi- 
bition of the enzyme is slightly greater than inhibition 
of virus replication-and not vice versa-a causal 
relationship is possible. 
DISCUSSION 
Using the enzyme preparations described above, 
four compounds were identified that are more potent 
inhibitors of the viral enzyme than of the cellular 
enzyme (Table 2). With the possible exception of 
ara-A-5’-triphosphate, no other compounds have 
been reported possessing such a large degree of 
selectivity (5 to >85fold difference) for the viral 
enzyme. Since cellular reductase was not inhibited 
50% by compounds 5 and 6 at the highest con- 
centrations tested, the selectivities for these two 
compounds may be even higher than noted. 
Thiosemicarbazone derivatives are known to be 
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potent chelating agents, forming coordination com- 
plexes with such transition metals as cobalt, nickel, 
copper and zinc [32]. These compounds are par- 
ticularly strong chelators of iron. Moore et al. [33] 
found that inhibition of mammalian ribonucleotide 
reductase activity correlates directly with the iron- 
chelating potency of a series of isoquinoline com- 
pounds. A similar result was seen here; the semi- 
carbazone (compound 6) was significantly (>170 
times) less inhibitory to either viral or cellular 
reductase than was the corresponding thiosemi- 
carbazone (compound 1). 
Insight into the mechanism of inhibition of mam- 
malian ribonucleotide reductase by thiosemicar- 
bazones was provided recently by Thelander and 
Grislund [34]. They showed that the iron chelate 
of 1-formylisoquinoline thiosemicarbazone destroys 
the tyrosine free radical at the active site of the M2 
subunit of reductase in a reaction requiring oxygen. 
They proposed that the ferrous chelate of the com- 
pound reacts with oxygen in a redox process leading 
to destruction of the radical via a one-electron 
reduction. If this mechanism is correct, the fact that 
the uncoordinated compounds used in this study 
inhibited reductase in the absence of added iron may 
result from the derivatives scavenging iron found as 
impurities in reaction components or enzyme 
preparations. 
The reported effects of thiol reducing agents on 
inhibition of mammalian ribonucleotide reductase 
by thiosemicarbazones are somewhat inconsistent. 
Moore et al. [33] found that inhibition by l-for- 
mylisoquinoline thiosemicarbazone is partially com- 
petitive with respect to DTT. Preidecker et al. [35] 
found that inhibition by MAIQ is uncompetitive with 
respect to thioredoxin. Competition also has been 
observed between DTT and another reductase 
inhibitor, hydroxyurea [36]. In the three reports, the 
true relationships may have been obscured due to 
the presence of various amounts of iron present in 
the assays, resulting in indeterminate redox reactions 
with the thiol reducing agents. 
In this study inhibition of the viral reductase by 
compound 1 was noncompetitive with respect to 
DTT. The difference between these and previous 
results may simply be due to the absence of iron in 
our enzyme assays. Alternatively, the results may 
suggest a difference between the active sites of cellu- 
lar and viral reductases. The active sites are thought 
to possess redox active sulfhydryl groups. Binding of 
an inhibitor to the iron atom or tyrosme free radical 
at the mammalian active site may sterically compete 
with the approach of thiol reducing agents needed to 
regenerate the sulfhydryl groups inactivated during 
catalysis, leading to competition between the thiol 
and drug. If the active site of the viral reductase 
were larger, steric hindrance would not occur and 
inhibition of drug would be noncompetitive with 
respect to thiol. The noncompetitive nature of com- 
pounds 1 and 2 with respect to CDP further suggests 
that the substrate and inhibitor sites on the viral 
reductase are spatially separate. 
The differences between the kinetic parameters 
measured for the two enzymes were relatively small. 
The average K,,, for CDP was slightly lower for 
viral reductase (1.2 ,uM) than for cellular reductase 
(2.2 PM). Previously reported K,,, concentrations for 
HSV-induced reductase range from 0.65 to 12 ,uM 
[18,37] whereas K,,, concentrations for mammalian 
cellular reductases range from 3.5 to 3OpM 
[3740]. The values obtained here were of a similar 
magnitude, lying near the lower ends of the reported 
ranges. 
The five thiosemicarbazone derivatives described 
herein also are potent inhibitors of the in vitro rep- 
lication of HSV-1 (1~s~ values range from 0.5 to 
6yM) [8]. As inhibitors of HSV-1 ribonucleotide 
reductase, their lcsO values range from 2 to 13 PM 
(Table 2). The similarity between these 50% inhibi- 
tory concentrations raised the possibility that inhi- 
bition of reductase may be responsible for inhibition 
of virus replication. A closer examination of the 
dose-response relationships for the parent com- 
pound 1 (Fig. 2) better illustrates the similarity 
between the two effects. The fact that viral reductase 
is slightly more sensitive to inhibition than is in vitro 
replication of virus suggests to us that inhibition of 
the viral enzyme is sufficient to account for the 
antiviral activity of this compound. 
This conclusion is opposite that reached by Nutter 
et al. [20]. They found that inhibition of viral ribo- 
nucleotide reductase by hydroxyurea did not cor- 
relate well with inhibition of HSV-2 replication. They 
also found that most viral ribonucleotide reductase 
activity was not needed for virus replication and 
concluded that “. . . virus ribonucleotide reductase 
is not an effective target for developing anti HSV-2 
compounds”. Our correlation data, of course, do not 
prove causality but the data are consistent with a 
causal relationship. Together with the observation 
that viral ribonucleotide reductase is needed for 
HSV-1 replication [15], we conclude that this enzyme 
is an important target for the development of anti- 
viral drugs. 
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